Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carilex MedicalROCO:7726 33 3-Year RORE % is 577.61 as of Dec. 2025. GuruFocus rates ROCO:7726 with a GF Score™ of 33/100. The stock has 5 warning signs investors should review. Among 772 Medical Devices & Instruments companies, Carilex Medical ranks better than 98.7% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Carilex Medical's 3-Year RORE % for the quarter that ended in Dec. 2025 was 577.61%.
The industry rank for Carilex Medical's 3-Year RORE % or its related term are showing as below:
ROCO:7726's 3-Year RORE % is ranked better than 98.7% of 772
companies
in the Medical Devices & Instruments industry
Industry Median: -4.05
vs ROCO:7726: 577.61
Carilex Medical (ROCO:7726) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Carilex Medical 3-Year RORE % Related Terms
Carilex Medical 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Carilex Medical's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7726 vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, Carilex Medical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carilex Medical 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carilex Medical's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Carilex Medical's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Carilex Medical (ROCO:7726) has a 3-Year RORE % of 577.61 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Carilex Medical and its competitors. According to the industry distribution chart, Carilex Medical ranks #10 out of 772 companies in the Medical Devices & Instruments industry, placing it in the top 1.3%.
Is Carilex Medical's 3-Year RORE % too high?
Carilex Medical's current 3-Year RORE % is 577.61. Based on the distribution chart, Carilex Medical ranks #10 out of 772 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Carilex Medical has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Carilex Medical ranks #10 out of 772 companies for 3-Year RORE %. This places Carilex Medical in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Carilex Medical and its competitors. Carilex Medical's current 3-Year RORE % is 577.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current 3-Year RORE % of 577.61. The current 3-Year RORE % is 577.61. Carilex Medical's overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current 3-Year RORE % is 577.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
33GF Score
Get the complete analysis for ROCO:7726
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7726 has been successfully added to your 
